全文获取类型
收费全文 | 1236篇 |
免费 | 133篇 |
国内免费 | 15篇 |
专业分类
耳鼻咽喉 | 4篇 |
儿科学 | 41篇 |
妇产科学 | 12篇 |
基础医学 | 174篇 |
口腔科学 | 19篇 |
临床医学 | 131篇 |
内科学 | 274篇 |
皮肤病学 | 10篇 |
神经病学 | 118篇 |
特种医学 | 150篇 |
外科学 | 83篇 |
综合类 | 69篇 |
预防医学 | 119篇 |
眼科学 | 13篇 |
药学 | 90篇 |
中国医学 | 2篇 |
肿瘤学 | 75篇 |
出版年
2023年 | 9篇 |
2022年 | 4篇 |
2021年 | 14篇 |
2020年 | 15篇 |
2019年 | 20篇 |
2018年 | 26篇 |
2017年 | 19篇 |
2016年 | 17篇 |
2015年 | 20篇 |
2014年 | 34篇 |
2013年 | 32篇 |
2012年 | 40篇 |
2011年 | 40篇 |
2010年 | 35篇 |
2009年 | 44篇 |
2008年 | 52篇 |
2007年 | 40篇 |
2006年 | 55篇 |
2005年 | 56篇 |
2004年 | 44篇 |
2003年 | 45篇 |
2002年 | 41篇 |
2001年 | 39篇 |
2000年 | 35篇 |
1999年 | 49篇 |
1998年 | 44篇 |
1997年 | 44篇 |
1996年 | 32篇 |
1995年 | 30篇 |
1994年 | 34篇 |
1993年 | 21篇 |
1992年 | 27篇 |
1991年 | 24篇 |
1990年 | 25篇 |
1989年 | 36篇 |
1988年 | 32篇 |
1987年 | 32篇 |
1986年 | 33篇 |
1985年 | 29篇 |
1984年 | 14篇 |
1983年 | 18篇 |
1982年 | 11篇 |
1981年 | 12篇 |
1980年 | 10篇 |
1979年 | 8篇 |
1978年 | 6篇 |
1977年 | 8篇 |
1975年 | 4篇 |
1974年 | 3篇 |
1968年 | 3篇 |
排序方式: 共有1384条查询结果,搜索用时 15 毫秒
21.
BackgroundSmall bowel involvement of Clostridium difficile is increasingly encountered. Data on many management aspects are lacking.AimTo synthesis existing reports and assess the frequency, pathophysiology, outcomes, risk factors, diagnosis and management of C. difficle enteritis.MethodsA systematic review of the literature was conducted to evaluate evidence regarding frequency, pathophysiology, risk factors, optimal diagnosis, management and outcomes for C. difficle enteritis. Three major databases (PubMed, MEDLINE and the Cochrane Library) were searched. The review included original articles reporting C. difficle enteritis from January 1950 to December 2012.ResultsC. difficle enteritis is rare but increasingly encountered. Presentation is variable and distinct predisposing factors include emergency surgery, white race and increased age. Diagnosis generally involves a sensitive but often non specific screening test for C. difficile antigens. Oral metronidazole represents first line therapy and surgery may be required for complications. Outcomes are inconsistent but may be improving.ConclusionsA high index of clinical suspicion, early diagnosis and treatment are vital. Further prospective studies are needed to determine the significance of asymptomatic small bowel C. difficile infections. 相似文献
22.
23.
24.
Marrow transplantation with or without donor buffy coat cells for 65 transfused aplastic anemia patients 总被引:4,自引:3,他引:4
Storb R; Doney KC; Thomas ED; Appelbaum F; Buckner CD; Clift RA; Deeg HJ; Goodell BW; Hackman R; Hansen JA; Sanders J; Sullivan K; Weiden PL; Witherspoon RP 《Blood》1982,59(2):236-246
Sixty-five multiply transfused patients with severe aplastic anemia were given cyclophosphamide followed by grafts anemia were given cyclophosphamide followed by grafts from HLA-identical siblings. The effect of the administration of viable donor buffy coat cells following the marrow inoculum was evaluated with regard to graft rejection and survival. Results in 43 patients so treated are presented along with those in 22 concurrent patients given marrow alone. Most patients given buffy coat had positive in vitro tests of sensitization indicating a high risk for graft rejection, while all but one of the patients given marrow alone had negative tests. Thirty of the 43 (70%) patients given marrow and buffy coat are alive between 10 and 61 mo (median 36) after grafting; 4 died after graft rejection and 6 with acute or chronic graft-versus-host disease (GVHD). Eleven of the 22 (50%) patients given marrow alone are alive between 29 and 65 mo (median 52); 7 died after graft rejection and 3 with GVHD. The addition of buffy coat cell infusions to the marrow inoculum reduced the risk of rejection and increased survival in the currently reported transfused patients when compared to patients grafted before 1976. However, there was an increased risk of chronic GVHD. Recipients of marrow from female donors survived slightly better (73%) than recipients of male marrow (58%). 相似文献
25.
26.
NA Hanchard DR Murdock PL Magoulas M Bainbridge D Muzny YQ Wu M Wang AL McGuire JR Lupski RA Gibbs CW Brown 《Clinical genetics》2013,83(5):457-461
The advent of whole‐exome next‐generation sequencing (WES) has been pivotal for the molecular characterization of Mendelian disease; however, the clinical applicability of WES has remained relatively unexplored. We describe our exploration of WES as a diagnostic tool in a 3½‐year old female patient with a 2‐year history of episodic muscle weakness and paroxysmal dystonia who presented following a previous extensive but unrevealing diagnostic work‐up. WES was performed on the proband and her two parents. Parental exome data was used to filter potential de novo genomic events in the proband and suspected variants were confirmed using di‐deoxy sequencing. WES revealed a de novo non‐synonymous mutation in exon 21 of the calcium channel gene CACNA1S that has been previously reported in a single patient as a rare cause of atypical hypokalemic periodic paralysis. This was unexpected, as the proband's original differential diagnosis had included hypokalemic periodic paralysis, but clinical and laboratory features were equivocal, and standard clinical molecular testing for hypokalemic periodic paralysis and related disorders was negative. This report highlights the potential diagnostic utility of WES in clinical practice, with implications for the approach to similar diagnostic dilemmas in the future. 相似文献
27.
28.
Alba Tristán-Noguero PhD Eva Borràs PhD Marta Molero-Luis PhD Tessa Wassenberg MD PhD Tessa Peters MSc Marcel M. Verbeek PhD Michel Willemsen MD PhD Thomas Opladen MD PhD Kathrin Jeltsch PhD Roser Pons MD PhD Beat Thony PhD Gabriella Horvath MD Zuhal Yapici MD Jennifer Friedman MD Keith Hyland PhD Guillermo E. Agosta MD Eduardo López-Laso MD Rafael Artuch MD PhD Eduard Sabidó PhD Àngels García-Cazorla MD PhD 《Movement disorders》2021,36(3):690-703
29.
30.
Ng AP Kauppi M Metcalf D Di Rago L Hyland CD Alexander WS 《Proceedings of the National Academy of Sciences of the United States of America》2012,109(7):2364-2369
Hematopoietic progenitor cells are the progeny of hematopoietic stem cells that coordinate the production of precise numbers of mature blood cells of diverse functional lineages. Identification of cell-surface antigen expression associated with hematopoietic lineage restriction has allowed prospective isolation of progenitor cells with defined hematopoietic potential. To clarify further the cellular origins of megakaryocyte commitment, we assessed the in vitro and in vivo megakaryocyte and platelet potential of defined progenitor populations in the adult mouse bone marrow. We show that megakaryocytes arise from CD150(+) bipotential progenitors that display both platelet- and erythrocyte-producing potential in vivo and that can develop from the Flt3(-) fraction of the pregranulocyte-macrophage population. We define a bipotential erythroid-megakaryocyte progenitor population, the CD150(+)CD9(lo)endoglin(lo) fraction of Lin(-)cKit(+)IL7 receptor alpha(-)FcγRII/III(lo)Sca1(-) cells, which contains the bulk of the megakaryocyte colony-forming capacity of the bone marrow, including bipotential megakaryocyte-erythroid colony-forming capacity, and can generate both erythrocytes and platelets efficiently in vivo. This fraction is distinct from the CD150(+)CD9(hi)endoglin(lo) fraction, which contains bipotential precursors with characteristics of increased megakaryocytic maturation, and the CD150(+)CD9(lo)endoglin(hi) fraction, which contains erythroid lineage-committed cells. Finally, we demonstrate that bipotential erythroid-megakaryocyte progenitor and CD150(+)CD9(hi)endoglin(lo) cells are TPO-responsive and that the latter population specifically expands in the recovery from thrombocytopenia induced by anti-platelet serum. 相似文献